Skip to main content
Pharmaron Beijing Co., Ltd logo

Pharmaron Beijing Co., Ltd — Investor Relations & Filings

Ticker · 3759 ISIN · CNE100003PG4 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 991 across all filing types
Latest filing 2021-08-13 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3759

About Pharmaron Beijing Co., Ltd

http://www.pharmaron.com

Pharmaron is a premier life science service provider and a comprehensive Contract Research and Manufacturing Organization (CRO/CDMO). The company delivers integrated research, development, and manufacturing capabilities across the entire drug development continuum, encompassing discovery, preclinical testing, clinical trials, and commercialization. Pharmaron's service portfolio supports diverse modalities, including small molecules, biologics, and advanced therapeutics such as cell and gene therapy (CGT) products. It partners with pharmaceutical, biotechnology, and medical device companies globally to advance their R&D pipelines.

Recent filings

Filing Released Lang Actions
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a notice of a board meeting scheduled to consider and approve the interim results for the six months ended June 30, 2021. It is an announcement about the timing and agenda of a board meeting, not the interim report itself. The document length is short (1543 characters) and it does not contain any financial data or detailed results. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) announcing the board meeting and the upcoming interim results approval.
2021-08-13 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-08-12 English
CONNECTED TRANSACTION IN RELATION TO INVESTMENT IN THE KANGJUN ZHONGYUAN FUND
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a connected transaction related to an investment in a fund (the Kangjun Zhongyuan Fund) by Pharmaron Beijing Co., Ltd. It details the terms of the Limited Partnership Agreement, capital contributions, management fees, and governance of the fund. The content focuses on a financing/investment transaction rather than financial results, management changes, or regulatory compliance filings. There is no indication that this is a full financial report, earnings release, or management discussion. The document is a detailed announcement about a capital investment transaction, which fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed terms of the investment, supporting this classification with high confidence.
2021-08-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 31 July 2021. It details movements in authorized/registered share capital, issued shares, share options, convertibles, and other share issuance arrangements. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited (HKEX) and contains detailed share capital and securities movement data. The document is not an annual or interim financial report, nor is it an earnings release or management discussion. It is a regulatory filing related to share capital movements and securities, consistent with a regulatory announcement rather than a full report. Given the nature and format, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-08-04 English
CONNECTED TRANSACTION IN RELATION TO INVESTMENT IN THE LEGEND HUIKANG FUND
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a connected transaction involving the company's investment in a fund (Legend Huikang Fund). It details the terms of the investment, parties involved, capital contributions, and regulatory implications under the Hong Kong Listing Rules. There are no financial statements or detailed financial performance data presented. The document is a disclosure of a financing-related transaction and investment update rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the transaction itself. The content fits best under Capital/Financing Update (CAP) as it relates to the company's capital investment activities and connected transaction disclosures.
2021-07-27 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2021-07-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.